Annual report pursuant to Section 13 and 15(d)

Income Taxes (Narrative) (Details)

v3.22.2.2
Income Taxes (Narrative) (Details) - USD ($)
 12 Months Ended
Apr. 23, 2023
Jun. 10, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Expense (Benefit) [Line Items]        
Corporate income tax rate     21.00% 21.00%
Unrecognized tax benefits     $ 0 $ 0
Penalties and interest expense     0 0
Income tax expense (benefit)     $ 236,397 (3,129,138)
Minimum [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards, expiration date     Dec. 31, 2023  
Maximum [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards, expiration date     Dec. 31, 2042  
Tax Period 2038 To 2042 [Member] | U.S. federal research and development tax credit carryforwards [Member]        
Income Tax Expense (Benefit) [Line Items]        
Tax credit carryforward     $ 8,500,000  
Tax Period 2038 To 2042 [Member] | Minimum [Member] | U.S. federal research and development tax credit carryforwards [Member]        
Income Tax Expense (Benefit) [Line Items]        
Tax credit carryforward, expiration date     Dec. 31, 2038  
Tax Period 2038 To 2042 [Member] | Maximum [Member] | U.S. federal research and development tax credit carryforwards [Member]        
Income Tax Expense (Benefit) [Line Items]        
Tax credit carryforward, expiration date     Dec. 31, 2042  
Domestic [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     $ 112,500,000  
Domestic [Member] | Tax Period 2023 To 2042 [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     29,700,000  
Domestic [Member] | Indefinite [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     82,800,000  
State [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     50,900,000  
State [Member] | Tax Period 2023 To 2042 [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     28,400,000  
State [Member] | Indefinite [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     22,500,000  
Foreign [Member] | Indefinite [Member]        
Income Tax Expense (Benefit) [Line Items]        
Operating loss carryforwards     63,100,000  
United States [Member]        
Income Tax Expense (Benefit) [Line Items]        
Valuation allowance     42,200,000 16,400,000
Valuation allowance, deferred tax asset, change in amount     25,800,000  
U.K. [Member]        
Income Tax Expense (Benefit) [Line Items]        
Increase in deferred tax assets       3,700,000
Valuation allowance, deferred tax asset, change in amount       700,000
Income tax expense (benefit)       (3,000,000.0)
U.K. [Member] | United Kingdom [Member]        
Income Tax Expense (Benefit) [Line Items]        
Corporate income tax rate   19.00%    
U.K. [Member] | Scenario, Forecast [Member] | Enacted U.K. Tax Rate Increase [Member]        
Income Tax Expense (Benefit) [Line Items]        
Corporate income tax rate 25.00%      
U.K. [Member] | The Female Health Company Limited [Member]        
Income Tax Expense (Benefit) [Line Items]        
Valuation allowance     3,200,000 $ 3,200,000
U.K. [Member] | The Female Health Company UK [Member]        
Income Tax Expense (Benefit) [Line Items]        
Valuation allowance     0  
U.K. [Member] | Veru Biopharma UK Limited [Member]        
Income Tax Expense (Benefit) [Line Items]        
Valuation allowance     $ 49,000